May 23, 2017
New bosses named in Summit Therapeutics
Summit Therapeutics, the drug discovery and development company advancing therapies for Duchenne muscular dystrophy (‘DMD’) and Clostridium difficile infection (‘CDI’), has appointed Dr David Roblin as Chief Medical Officer, Anne Heatherington, PhD, as Head of Clinical Development and Quantitative Sciences and Dave Powell, PhD, as Head of Research.